Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. [electronic resource]
Producer: 20180101Description: 193-201 p. digitalISSN:- 1573-7373
- Adult
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- therapeutic use
- Bortezomib -- therapeutic use
- Brain Neoplasms -- drug therapy
- Dacarbazine -- analogs & derivatives
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Glioblastoma -- drug therapy
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Retrospective Studies
- Temozolomide
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.